Clovis spikes ovarian cancer combo after 'underwhelming' efficacy; Servier wins priority review for Tibsovo expansion
Clovis Oncology updated investors with its first quarter results on Wednesday morning, and among its revelations proved some troubling news for a Bristol Myers Squibb-partnered program.
Pairing its experimental lucitanib drug with Bristol Myers’ Opdivo in an ongoing Phase Ib/II study, Clovis reported that “underwhelming efficacy” has led them to cease development for the combo in non-clear-cell ovarian cancer, execs said in Wednesday morning’s earnings call. Enrollment is continuing in other expansion cohorts, which include non-clear cell endometrial cancer, cervical cancer and clear-cell ovarian and endometrial cancers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.